Tg Therapeutics (TGTX) Accounts Payables (2013 - 2026)

Tg Therapeutics' Accounts Payables history runs 14 years deep, the most recent figure standing at $148.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 429.7% year-over-year to $148.8 million in Q1 2026; TTM through Mar 2026 was $148.8 million, a 429.7% increase from a year earlier, with the FY2025 full-year figure at $107.5 million, up 84.42% from the prior year.
• Accounts Payables rose to $148.8 million in Q1 2026 per TGTX's latest filing, from $107.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $148.8 million in Q1 2026 and bottomed at $28.1 million in Q1 2025.
• The 5-year median for Accounts Payables is $58.3 million (2024), against an average of $72.2 million.
• Across the five-year window, Accounts Payables tumbled 67.8% in 2025 and surged 429.7% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $42.0 million in 2022, then decreased by 8.44% to $38.5 million in 2023, then surged by 51.53% to $58.3 million in 2024, then surged by 84.42% to $107.5 million in 2025, then jumped by 38.45% to $148.8 million in 2026.
• Per Business Quant, the three latest TGTX Accounts Payables figures stand at $148.8 million (Q1 2026), $107.5 million (Q4 2025), and $112.3 million (Q3 2025).